Drug repurposing aims to find new uses for existing medicines to treat conditions with unmet medical needs. This developing field has the potential to be less costly and significantly quicker than traditional drug discovery. This makes it a valid, attractive strategy especially for rare and neglected conditions, cancer or emerging public health threats such as COVID-19.

Yet, numerous barriers —economic, regulatory, policy— and inefficiencies —fragmented ecosystem, limited knowledge about the complete repurposing pathway, funding gaps— are still holding back drug repurposing.

**OUR VISION**

With the backing of the European Union, REMEDI4ALL is set to revolutionise the repurposing landscape in Europe by:

- Developing a comprehensive, accessible and standardised platform that provides the expertise, tools and resources required in all stages of the repurposing journey. This will ensure that more (and better) repurposed medicines are available to patients and will contribute to more sustainable health systems.

- Generating a more favourable policy environment for drug repurposing by bringing together key stakeholders in a forum of debate to identify current barriers and explore creative solutions and incentives.

- Building a dynamic global community practising drug repurposing.

**Drugs repurposing potentially stands for more efficient research with high social impact as it offers a cost-effective and relatively quick route to a much-needed treatment**

**KEY FACTS & FIGURES**

- **DURATION**: 2022-2027
- **FUNDING**: 25 million €
- **LEADER**: EATRIS
- **TYPE OF ACTION**: Research and Innovation Action (RIA)
- **PROGRAMME**: Horizon Europe
EXPERTISE AND COLLABORATION

Under the leadership of EATRIS, the European infrastructure for translational medicine, **24 European organisations** are closely collaborating to improve the existing ecosystem and make drug repurposing the new normal.

**REMEDi4ALL partners** bring a unique mix of expertise in the fields of:
- Patient engagement and co-design
- In silico and computational methods
- In vitro and in vivo nonclinical drug development
- Drug screening
- Clinical operations and trial management
- Regulatory science
- Research funding
- Health technology and reimbursement
- Policy and eco-system monitoring

THREE ADVISORY BOARDS BRINGING TOGETHER ALL INTEREST GROUPS

→ Policy Board
→ Ethics Board
→ Stakeholder Forum

FOUR PILOT PROJECTS TO TEST AND OPTIMISE THE NEW PLATFORM

→ Pancreatic cancer
→ COVID-19
→ Osteogenesis imperfecta
→ Multiple Sulfatase Deficiency

“A strong international Consortium of 24 leading organisations with diverse expertise to enable game-changing innovation”

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101057442. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union, who cannot be held responsible for them. This presentation reflects only the author’s view. The EU is not responsible for any use that may be made of the information it contains.